News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tauriga Sciences Inc. (TAUG) Executes Investment Banking Agreement With Tokyo, Japan Based Dragoon Capital Inc.


8/25/2014 7:45:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that it has entered into an investment banking agreement with Tokyo, Japan based investment banking firm Dragoon Capital, Inc. ("Dragoon"). Through this investment banking agreement, Dragoon has agreed on a best efforts basis to secure the Company a private placement equity capital financing from its extensive base of both Japanese institutional and accredited individual investors. The proceeds from this private placement, if and when complete, should enable the Company to expand its medicinal cannabis and complementary natural wellness businesses as well as provide Pilus Energy with capital as it advances its pilot test program with the Metropolitan Sewer District of Greater Cincinnati ("MSDGC") and the EPA T&E department (Environmental Protection Agency's Testing & Evaluation department).

Dragoon Capital Inc. is an independent investment banking firm that specializes in advising and funding emerging growth companies in Japan and worldwide. The shares offered under this investment banking agreement will be offered solely to Japanese domiciled institutional and accredited individual investors. The Company is also exploring the possibility of expanding some of its product lines to the Japanese marketplace.

Tauriga's CEO, Dr. Stella M.Sung commented, "The Company is pleased to sign this investment banking agreement with Dragoon Capital and is excited to enhance its presence and visibility in the Japanese investor community. The Company is actively seeking opportunities to increase revenue and expand into new markets, both domestically and internationally."

Dragoon Capital Inc. CEO Shuichi Uda stated, "Our investment banking firm is delighted to represent Tauriga Sciences, Inc. to the Japanese investment community. After careful due diligence, it was clear that Tauriga has a highly qualified management team and significant business opportunities in compelling growth segments of the market. We look forward to watching Tauriga evolve with the benefit of additional growth capital."

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of life science assets that is capital efficient and has the potential to generate meaningful profitable revenues. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On July 15, 2014, Tauriga acquired a California based topical cannabis cream company. Please visit the Company's corporate website at www.tauriga.com.

About Dragoon Capital, Inc.

Dragoon Capital Inc. is an independent investment banking firm that provides advice to institutional investors and middle-market and emerging growth companies in Japan and worldwide. Together, the firm's management professionals have more than 80 years of experience providing private and public companies with a broad spectrum of investment banking and financial advisory services, including: mergers and acquisitions; equity and debt capital raises; and restructurings. The firm provides objective, unbiased, results-focused services that clients need to achieve their goals. For more information, please visit: http://www.dragoon.co.jp/en/index.html

NON SOLICITATION:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration. In addition the above mentioned investment banking agreement with Dragoon Capital is contractually on a best efforts basis.

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

CONTACT: Tauriga Sciences, Inc.: Dr. Stella M. Sung Chairman and Chief Executive Officer Tauriga Sciences, Inc. www.tauriga.com San Diego: + 1-858-353-5749 Montreal: + 1-514-840-3697 Email: ssung@tauriga.com

Tauriga logo

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES